21 June 2016 - Eli Lilly Canada announced today that Health Canada has granted approval for Taltz (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis in Canadian adults who are candidates for systemic therapy or phototherapy.

Health Canada's approval of Taltz is based on data from three double-blind multicentre Phase III studies – UNCOVER-1, UNCOVER-2, and UNCOVER-3 – which evaluated more than 3,800 patients (over 650 Canadians) with moderate-to-severe plaque psoriasis from 21 countries, involving more than 35 Canadian physicians. This number includes patients who began the trials on Taltz, placebo, or active comparator (etanercept).

For more details, go to: http://www.newswire.ca/news-releases/health-canadas-approval-of-taltz-ixekizumab-brings-targeted-therapy-to-canadians-living-with-moderate-to-severe-plaque-psoriasis-583815191.html